Effect of Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion on Parkinson's Disease-Related Pain: A 6-Month Real-World Longitudinal Study.

IF 3.4 4区医学 Q2 CLINICAL NEUROLOGY

Movement Disorders Clinical Practice Pub Date : 2026-10-04 DOI:10.1002/mdc3.70849

Kristi Meksi, Clara Simonetta, Valerio Ferrari, Giovanni Minutilli, Matteo Conti, Francesca Avvento, Tommaso Schirinzi, Diego Centonze, Alessandro Stefani, Mariangela Pierantozzi

{"title":"Effect of Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion on Parkinson's Disease-Related Pain: A 6-Month Real-World Longitudinal Study.","authors":"Kristi Meksi, Clara Simonetta, Valerio Ferrari, Giovanni Minutilli, Matteo Conti, Francesca Avvento, Tommaso Schirinzi, Diego Centonze, Alessandro Stefani, Mariangela Pierantozzi","doi":"10.1002/mdc3.70849","DOIUrl":null,"url":null,"abstract":"Background: Foslevodopa/foscarbidopa (LDp/CDp) infusion may reduce PD-related pain; however, its effects on different pain manifestations remain unclear.Objective: The aim was to evaluate longitudinal changes in overall and domain-specific PD-related pain after LDp/CDp infusion.Methods: Twenty-six patients with advanced PD initiating LDp/CDp infusion underwent evaluation at baseline (T0) and 6 months (T1). Pain was assessed using the King's Parkinson's Disease Pain Scale (KPPS). Secondary outcomes included motor complications, quality of life (QoL), dopaminergic treatment burden, and pain-motor correlations.Results: At T1, KPPS total score decreased (9.6 ± 6.5 vs. 2.7 ± 4.7, P < 0.001), with improvements in chronic (P = 0.01), fluctuation-related (P < 0.001), and nocturnal (P < 0.001) pain. Motor complications reduced (P < 0.001), and fluctuation-related pain reduction correlated with motor complication changes (ρ = 0.46, P = 0.04). QoL improved (P = 0.006), whereas dopaminergic treatment burden was unchanged.Conclusions: LDp/CDp infusion improved PD-related pain, particularly chronic, fluctuation-related, and nocturnal pain, with a parallel improvement in QoL, suggesting benefits beyond motor complication management.","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2026-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13635645/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Movement Disorders Clinical Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/mdc3.70849","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Foslevodopa/foscarbidopa (LDp/CDp) infusion may reduce PD-related pain; however, its effects on different pain manifestations remain unclear.

Objective: The aim was to evaluate longitudinal changes in overall and domain-specific PD-related pain after LDp/CDp infusion.

Methods: Twenty-six patients with advanced PD initiating LDp/CDp infusion underwent evaluation at baseline (T0) and 6 months (T1). Pain was assessed using the King's Parkinson's Disease Pain Scale (KPPS). Secondary outcomes included motor complications, quality of life (QoL), dopaminergic treatment burden, and pain-motor correlations.

Results: At T1, KPPS total score decreased (9.6 ± 6.5 vs. 2.7 ± 4.7, P < 0.001), with improvements in chronic (P = 0.01), fluctuation-related (P < 0.001), and nocturnal (P < 0.001) pain. Motor complications reduced (P < 0.001), and fluctuation-related pain reduction correlated with motor complication changes (ρ = 0.46, P = 0.04). QoL improved (P = 0.006), whereas dopaminergic treatment burden was unchanged.

Conclusions: LDp/CDp infusion improved PD-related pain, particularly chronic, fluctuation-related, and nocturnal pain, with a parallel improvement in QoL, suggesting benefits beyond motor complication management.

查看原文本刊更多论文

持续皮下注射Foslevodopa/Foscarbidopa对帕金森病相关疼痛的影响：一项为期6个月的真实世界纵向研究

背景：Foslevodopa/foscarbidopa （LDp/CDp）输注可减轻pd相关疼痛；然而，它对不同疼痛表现的影响尚不清楚。目的：目的是评估LDp/CDp输注后pd相关疼痛的整体和特定领域的纵向变化。方法：26例晚期PD患者启动LDp/CDp输注，在基线（T0）和6个月（T1）时进行评估。疼痛采用国王帕金森病疼痛量表（KPPS）进行评估。次要结局包括运动并发症、生活质量（QoL）、多巴胺能治疗负担和疼痛-运动相关性。结果：在T1时，KPPS总分下降（9.6±6.5 vs. 2.7±4.7）P结论：LDp/CDp输注改善pd相关疼痛，特别是慢性、波动相关疼痛和夜间疼痛，同时改善生活质量，表明其益处超出了运动并发症的管理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Movement Disorders Clinical Practice CLINICAL NEUROLOGY-

CiteScore

4.00

自引率

7.50%

发文量

218

期刊介绍： Movement Disorders Clinical Practice- is an online-only journal committed to publishing high quality peer reviewed articles related to clinical aspects of movement disorders which broadly include phenomenology (interesting case/case series/rarities), investigative (for e.g- genetics, imaging), translational (phenotype-genotype or other) and treatment aspects (clinical guidelines, diagnostic and treatment algorithms)